SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense community debate following an earnings report that significantly beat analyst expectations and featured strong forward guidance, though the stock faced immediate volatility due to broader market macro concerns and profit-taking after a recent steep rally. Investors remain divided, with some viewing the pullback as a strategic buying opportunity driven by AI-fueled memory demand, while others caution that the rapid share price appreciation has already priced in the company's growth.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to critical supply chain disruptions in the Middle East, specifically the closure of major LNG facilities in Qatar and escalating tensions near the Strait of Hormuz. The community is actively discussing the company's potential to capitalize on elevated spot prices and increased demand, while also debating the long-term impact of geopolitical uncertainty on global energy security.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme market volatility and high retail interest as traders debate whether its combat-proven drone software justifies a massive valuation following a recent IPO. The community is actively tracking the stock's parabolic climb while speculating on potential defense contracts and the implications of its limited float on near-term price momentum.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trending as investors weigh conflicting signals between safe-haven demand due to Middle East geopolitical instability and persistent inflation concerns driven by volatile energy prices. The community is actively debating the implications of Federal Reserve interest rate policy, the long-term sustainability of deficit spending, and the impact of the oil shock on the broader macroeconomic outlook.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing intense selling pressure and high volatility following the unveiling of Googles AI simulation prototype, which traders fear could challenge the companys gaming dominance. The community remains deeply divided, with bears pointing to ongoing safety concerns and regulatory hurdles, while bulls are actively accumulating shares and looking for a reversal based on long-term growth metrics.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as investors react to a significant 13G filing revealing that Steven Cohen's Point72 Asset Management has taken a major stake, fueling momentum alongside optimism regarding positive clinical data. The community is heavily focused on the company's limited float and potential for a strategic partnership or buyout, though skepticism remains among some traders regarding the stock's volatility and the prospect of future equity offerings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is seeing massive investor interest and heightened volatility, fueled by a broader sector-wide surge in memory chip demand tied to AI infrastructure. While the community is split between bullish sentiment over long-term supply shortages and bearish warnings that the stock is reaching an unsustainable, overextended peak, participants are closely monitoring upcoming earnings reports for key industry peers as a critical catalyst for the next major price movement.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is facing heightened volatility as investors weigh strong AI-driven data storage demand and a new $4 billion share buyback program against technical pressure from the ongoing divestment of its SanDisk stake. While the memory sector remains a focal point for long-term growth, the community is actively debating whether recent pullbacks represent a healthy consolidation for a supercycle or the peak of a speculative AI-fueled rally.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant momentum as traders debate whether the surge is driven by legitimate AI-linked growth or potential market manipulation, with the community highlighting heavy institutional volume and intense short-covering. The conversation remains sharply divided between bulls anticipating a climb toward triple digits and bears skeptical of the company's lack of profitability and heavy insider selling.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is attracting significant attention as investors weigh the firm's strategic pivot toward generative AI against persistent concerns regarding slowing IT spending and workforce restructuring. The community is actively debating the stock's long-term viability, with many closely watching how high-profile AI partnerships and recent executive leadership moves will influence the stock's recovery from its current technical downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.&nbsp;</li><li>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises.</li><li>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde.</li></ul><p>Wall Street on Wednesday reiterated confidence in Protagonist Therapeutics (PTGX) after John and Johnson received U.S. Food and Drug Administration’s approval for Icotyde for the treatment of moderate-to-severe plaque psoriasis.</p><p>The FDA approved the drug in adults and pediatric patients 12 years of age and older. The approval was based on four late-stage studies that met all primary endpoints and demonstrated a favorable safety profile in 2,500 patients.</p><h2 class="st-heading-2">Protagonist’s Role In Icotyde</h2><p>Icotyde was jointly discovered by Protagonist and Johnson &amp; Johnson but it will now be commercialized by Johnson &amp; Johnson alone under a license and collaboration agreement established in 2017.</p><p>FDA approval of Icotyde triggers a $50 million milestone payment to Protagonist, the company said, while adding that it is eligible eligible to receive up to $580 million in potential additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales.</p><h2 class="st-heading-2">Analyst Take</h2><p>H.C. Wainwright analyst Douglas Tsao said that while Icotyde's approval was expected, the earlier than expected approval and "clean" label represent upside surprises. Johnson &amp; Johnson is committed to building Icotyde into a blockbuster, which should create "significant value" for Protagonist Therapeutics (PTGX), the analyst told investors in a research note.</p><p>H.C. Wainwright believes Icotyde is positioned to "transform the plaque psoriasis landscape with a differentiated label that highlights its superior efficacy and safety profile." The firm reiterated a ‘Buy’ rating on Protagonist with a $117 price target.</p><p>Clear Street raised the firm's price target on Protagonist Therapeutics to $104 from $91 and kept a ‘Buy’ rating on the shares following the FDA approval of Icotyde. The approval transitions Protagonist into a company with royalty-bearing commercial exposure, while retaining upside from lifecycle expansion and the broader pipeline, the firm said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around PTGX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/PTGX">PTGX stock</a> has gained 78% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fed-chair-powell-says-iran-war-will-spike-inflation-in-the-near-term-but-too-soon-to-assess-impact/cZ37Nb9RIW5">Fed Chair Powell Says Iran War Will Spike Inflation In The Near Term, But Too Soon To Assess Impact</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Global stock market chart and trading board - stock photo

Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 

Equity

The FDA approved the drug for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older on Wednesday. 


Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - What's Next...

Protagonist Therapeutics, Inc. $PTGX Holdings Boosted by HighVista Strategies LLC

HighVista Strategies LLC increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 110.3% in the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are covering the stock, MarketBeat Ratings reports...

Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC

Boxer Capital Management LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 83.3% during the 3rd quarter, according to the company in its most recent filing with...

Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX

Commodore Capital LP lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 4.7% in the third quarter, according to the company in its most recent Form 13F...

Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Mangrove Partners IM LLC

Mangrove Partners IM LLC lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.0% during the third quarter, according to its most recent disclosure with...

Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 18. (View Earnings Report at...

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High - Should You Buy?

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's Why...

Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX

Intech Investment Management LLC cut its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 36.3% during the third quarter, according to its most recent 13F filing with the...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.49	--	--	N/A
Q4 '25	-$0.35	-$0.69	-97.86%	MISSED
Q3 '25	-$0.60	-$0.62	-3.11%	MISSED
Q2 '25	-$0.53	-$0.55	-4.10%	MISSED
Q1 '25	-$0.19	--	--	N/A

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest PTGX News

PTGXProtagonist Therapeutics Inc